Hypercapnic ventilatory response for Parkinson's (NCT06074614)
Understand brain control of breathing
- Trial ID
- NCT06074614
- Official Title
- Neural Control of Breathing in Parkinson's Disease: an Exploratory Study
- Goal
- Understand brain control of breathing
- Status
- RECRUITING
- Sponsor
- Radboud University Medical Center
- Study Type
- OBSERVATIONAL
- Enrollment
- 30 participants
- Conditions
- Parkinson Disease
- Interventions
- Hypercapnic ventilatory response, Respiratory related evoked potential, Transcranial magnetic stimulation
Summary For Families
The goal is to learn how Parkinson's affects the brain's control of breathing, which can help explain symptoms like a blunted response to rising carbon dioxide, cough or swallow problems, and breathlessness. The team will raise CO2 briefly to measure ventilatory drive, record electrical brain responses to breathing loads with respiratory related evoked potentials, and use noninvasive transcranial magnetic stimulation to activate motor brain areas and test how well respiratory pathways respond. Adults 18 and older are eligible, including people with Parkinson's at Hoehn and Yahr stages 1 to 3 and healthy volunteers, while people with other CNS diseases, major lung disease, implanted electronic or certain metal head devices, pregnancy, smoking, epilepsy or prior brain surgery are excluded.
Locations
- Radboudumc, Nijmegen, Gelderland, Netherlands
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Hypercapnic ventilatory response. The goal is to learn how Parkinson's affects the brain's control of breathing, which can help explain symptoms like a blunted response to rising carbon dioxide, cough or swallow problems, and breathlessness. The team will raise CO2 briefly to measure ventilatory drive, record electrical brain responses to breathing loads with respiratory related evoked potentials, and use noninvasive transcranial magnetic stimulation to activate motor brain areas and test how well respiratory pathways respond. Adults 18 and older are eligible, including people with Parkinson's at Hoehn and Yahr stages 1 to 3 and healthy volunteers, while people with other CNS diseases, major lung disease, implanted electronic or certain metal head devices, pregnancy, smoking, epilepsy or prior brain surgery are excluded.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 6 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.